09.01.01
The National Cancer Institute (NCI), Bethesda, MD, has launched a randomized clinical trial to test the effects of shark cartilage in combination with chemotherapy and radiotherapy in patients with non-small cell lung cancer that cannot be removed by surgery. The study will take place at more than 50 sites throughout the U.S. and Canada and will seek to enroll 756 patients over the next three years. It is expected that the results from this trial will be available in approximately five years.
In other news, NCI and the University of Pittsburgh Cancer Institute (UPCI) has launched the largest ever prostate cancer prevention trial. The study, which will include a total of 32,400 men, is being conducted through a network of research sites known as the Southwest Oncology Group (SWOG), of which UPCI is a member. The Selenium and Vitamin E Cancer Prevention Trial, or SELECT, seeks to learn if these two dietary supplements can protect against prostate cancer. More than 400 sites in the U.S., Puerto Rico and Canada are recruiting participants for SELECT, which will take up to 12 years to complete.
In other news, NCI and the University of Pittsburgh Cancer Institute (UPCI) has launched the largest ever prostate cancer prevention trial. The study, which will include a total of 32,400 men, is being conducted through a network of research sites known as the Southwest Oncology Group (SWOG), of which UPCI is a member. The Selenium and Vitamin E Cancer Prevention Trial, or SELECT, seeks to learn if these two dietary supplements can protect against prostate cancer. More than 400 sites in the U.S., Puerto Rico and Canada are recruiting participants for SELECT, which will take up to 12 years to complete.